These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

83 related articles for article (PubMed ID: 6064867)

  • 41. Concentrated preparations of Factor 8 (antihaemophilic globulin) in the management of haemophilia A and von Willebrand's disease.
    Castaldi PA; Somer JB; Schiff P; Blackburn CR
    Med J Aust; 1967 Sep; 2(11):481-5. PubMed ID: 5299300
    [No Abstract]   [Full Text] [Related]  

  • 42. Evaluation of human viral disease transmission through plasma products.
    Heldebrant CM; Friedman AE; Fedor EJ
    Dev Biol Stand; 1987; 67():319-22. PubMed ID: 2440744
    [TBL] [Abstract][Full Text] [Related]  

  • 43. In vivo recovery of factor VIII following transfusion: a survey of recent data and publications to assess the influence of standards used for potency assignment. On behalf of the Subcommittee on Factor VIII and IX of the Scientific and Standardization Committee of the ISTH.
    Prowse CV
    Thromb Haemost; 1995 Oct; 74(4):1191-6. PubMed ID: 8560434
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Treatment of hemorrhage in hemophilia.
    Med Lett Drugs Ther; 1967 Apr; 9(8):31-2. PubMed ID: 6040171
    [No Abstract]   [Full Text] [Related]  

  • 45. [Therapy of hemophilia A with a cryoprecipitated antihemophilic factor].
    Ollendorff P
    Ugeskr Laeger; 1969 May; 131(20):877-81. PubMed ID: 5795169
    [No Abstract]   [Full Text] [Related]  

  • 46. [Opportune treatment of hemorrhage in classical hemophilia. Study of the Hemophilia Cooperative Group].
    Rodríguez-Moyado H; Ambriz-Fernández R; Pizzuto-Chávez J; Farfán-Canto JM; Hernández-Lugo MI; Guillén-Mariscal C; Ramírez-Ortiz G; Benítez-Aranda H
    Bol Med Hosp Infant Mex; 1986 Dec; 43(12):742-9. PubMed ID: 3101718
    [No Abstract]   [Full Text] [Related]  

  • 47. High purity factor VIII and immune state in HIV.
    Nurs Stand; 1993 Oct 6-12; 8(3):17. PubMed ID: 8217692
    [No Abstract]   [Full Text] [Related]  

  • 48. Worldwide overview of plasma procurement and fractionation.
    Britten AF; Ala F; Carman C; Smit Sibinga CT
    Scand J Haematol Suppl; 1984; 40():479-84. PubMed ID: 6433468
    [No Abstract]   [Full Text] [Related]  

  • 49. Use of porcine factor VIII for surgical procedures in hemophilia A patients with inhibitors.
    Lozier JN; Santagostino E; Kasper CK; Teitel JM; Hay CR
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):10-21. PubMed ID: 8480192
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Companies try different plans for same clotting factor product.
    Thompson CA
    Am J Health Syst Pharm; 2001 Jan; 58(1):16, 20. PubMed ID: 11194129
    [No Abstract]   [Full Text] [Related]  

  • 51. The treatment of acquired factor VIII inhibitors: worldwide experience with porcine factor VIII concentrate. International Acquired Hemophilia Study Group.
    Kessler CM; Ludlam CA
    Semin Hematol; 1993 Apr; 30(2 Suppl 1):22-7. PubMed ID: 8480193
    [No Abstract]   [Full Text] [Related]  

  • 52. Development and present status of concentrate therapy for hemophilia and von Willebrand's disease.
    Brinkhous KM
    Wien Klin Wochenschr; 1982 Oct; 94(19):509-14. PubMed ID: 6818773
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A regional redistribution programme for the optimal management of clotting factor concentrates prescribed by haemophilia treatment centres.
    Crymble S; Anderson M; Travas A; Floros G; Teitel J
    Transfus Med; 2013 Oct; 23(5):370-2. PubMed ID: 23763626
    [No Abstract]   [Full Text] [Related]  

  • 54. [Hemophilia, a changed picture].
    Breederveld C; ten Cate JW; Sixma JJ; Veltkamp JJ
    Ned Tijdschr Geneeskd; 1976 Jan; 120(2):69-70. PubMed ID: 1250448
    [No Abstract]   [Full Text] [Related]  

  • 55. [Side-effects of factor VIII substitution in patients with hemophilia A (author's transl)].
    Tilsner V; Reuter H
    MMW Munch Med Wochenschr; 1982 Jun; 124(22):553-7. PubMed ID: 6808385
    [No Abstract]   [Full Text] [Related]  

  • 56. Coagulation factor VIII concentrates and the marketplace.
    Cash JD
    Lancet; 1988 Jun; 1(8597):1270. PubMed ID: 2897528
    [No Abstract]   [Full Text] [Related]  

  • 57. Purification of antihemophilic factor (AHF) for clinical and experimental use.
    Johnson AJ; Newman J; Howell MB; Puszkin S
    Thromb Diath Haemorrh Suppl; 1967; 26():377-81. PubMed ID: 6064868
    [No Abstract]   [Full Text] [Related]  

  • 58. Report of the subcommittee for the standardization of factor VIII.
    Biggs R
    Thromb Diath Haemorrh Suppl; 1968; 35():223-9. PubMed ID: 4953166
    [No Abstract]   [Full Text] [Related]  

  • 59. Factor VIII supply and demand.
    Jones P
    Br Med J; 1980 Jun; 280(6230):1531-2. PubMed ID: 6770954
    [No Abstract]   [Full Text] [Related]  

  • 60. Factor VIII supply and demand.
    Br Med J; 1980 Oct; 281(6246):1006. PubMed ID: 6775753
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.